ES2149733T1 - Composicion farmaceutica oral con liberacion modificada que contiene 5-asa y metodo para el tratamiento de enfermedades intestinales. - Google Patents

Composicion farmaceutica oral con liberacion modificada que contiene 5-asa y metodo para el tratamiento de enfermedades intestinales.

Info

Publication number
ES2149733T1
ES2149733T1 ES96943884T ES96943884T ES2149733T1 ES 2149733 T1 ES2149733 T1 ES 2149733T1 ES 96943884 T ES96943884 T ES 96943884T ES 96943884 T ES96943884 T ES 96943884T ES 2149733 T1 ES2149733 T1 ES 2149733T1
Authority
ES
Spain
Prior art keywords
asa
treatment
pharmaceutical composition
modified release
oral pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES96943884T
Other languages
English (en)
Other versions
ES2149733T5 (es
ES2149733T3 (es
Inventor
Svenn Kluver Jepsen
Soren Halskov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farmaceutisk Laboratorium Ferring AS
Original Assignee
Farmaceutisk Laboratorium Ferring AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24302375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2149733(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Farmaceutisk Laboratorium Ferring AS filed Critical Farmaceutisk Laboratorium Ferring AS
Publication of ES2149733T1 publication Critical patent/ES2149733T1/es
Application granted granted Critical
Publication of ES2149733T3 publication Critical patent/ES2149733T3/es
Publication of ES2149733T5 publication Critical patent/ES2149733T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBE UNA COMPOSICION FARMACEUTICA DE LIBERACION MODIFICADA Y UN PROCEDIMIENTO PARA EL TRATAMIENTO DE ENFERMEDADES DEL INTESTINO INFLAMATORIAS (IBD), TAL COMO LA ENFERMEDAD DE CROHN Y LA COLITIS ULCEROSA, INCLUYENDO DICHAS COMPOSICIONES COMO PRINCIPIO ACTIVO EL INGREDIENTE ACIDO 5 - AMINOSALICILICO (5 ASA), Y ESTANDO ADAPTADAS PARA LA LIBERACION MODIFICADA Y DIRIGIDA, PARA OBTENER UN PERFIL DE EFECTO LOCALIZADO IMPORTANTE DESDE EL PUNTO DE VISTA CLINICO DE 5 - ASA, MEDIANTE LA LIBERACION DE UNA CANTIDAD APROPIADA DE 5 - ASA EN EL INTESTINO DELGADO Y GRUESO.
ES96943884T 1995-12-21 1996-12-23 Composicion farmaceutica oral de liberacion modificada que contiene 5-asa y metodo para el tratamiento de enfermedades intestinales. Expired - Lifetime ES2149733T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57595495A 1995-12-21 1995-12-21
US575954 1995-12-21

Publications (3)

Publication Number Publication Date
ES2149733T1 true ES2149733T1 (es) 2000-11-16
ES2149733T3 ES2149733T3 (es) 2002-04-01
ES2149733T5 ES2149733T5 (es) 2008-05-01

Family

ID=24302375

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96943884T Expired - Lifetime ES2149733T5 (es) 1995-12-21 1996-12-23 Composicion farmaceutica oral de liberacion modificada que contiene 5-asa y metodo para el tratamiento de enfermedades intestinales.

Country Status (27)

Country Link
EP (1) EP0871434B2 (es)
JP (1) JP4714836B2 (es)
KR (2) KR100542544B1 (es)
CN (1) CN1155369C (es)
AT (1) ATE205704T1 (es)
AU (1) AU702934B2 (es)
BG (1) BG63484B1 (es)
BR (1) BR9612213A (es)
CA (1) CA2240281C (es)
CZ (1) CZ289290B6 (es)
DE (2) DE871434T1 (es)
DK (1) DK0871434T4 (es)
EE (1) EE03740B1 (es)
ES (1) ES2149733T5 (es)
HU (1) HU228856B1 (es)
IL (1) IL124858A (es)
IS (1) IS1834B (es)
NO (1) NO320498B1 (es)
NZ (1) NZ325201A (es)
PL (1) PL186790B1 (es)
PT (1) PT871434E (es)
RU (1) RU2181043C2 (es)
SI (1) SI0871434T2 (es)
SK (1) SK282669B6 (es)
TR (1) TR199801158T2 (es)
UA (1) UA67721C2 (es)
WO (1) WO1997023199A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
JP2002535353A (ja) 1999-01-29 2002-10-22 ロザン ファルマ ゲゼルシャフトミットベシュレンクテルハフツンク 医薬品組成物
RU2191782C2 (ru) * 2000-09-21 2002-10-27 Институт нефтехимии и катализа АН РБ и УНЦ РАН Способ получения модифицированной гиалуроновой кислоты
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
RU2286156C2 (ru) * 2001-10-15 2006-10-27 Ферринг Бв Способ приготовления фармацевтической композиции, включающей в себя 5-аминосалициловую кислоту, для применения в лечении неспецифического язвенного колита и болезни крона
CN100506234C (zh) * 2001-10-15 2009-07-01 凡林有限公司 用于治疗溃疡性结肠炎和克罗恩病的含有5-氨基水杨酸的药物组合物的制备方法
US8282955B2 (en) * 2001-10-15 2012-10-09 Ferring B.V. Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease
WO2004093883A2 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
EP1547601A1 (en) * 2003-12-23 2005-06-29 Ferring B.V. Coating method
RU2297835C1 (ru) 2005-09-26 2007-04-27 Закрытое акционерное общество "Партнер" Препарат для лечения неинфекционных воспалительных болезней кишечника
EP2004164B1 (en) * 2006-04-13 2018-08-08 Neurotech Pharmaceuticals Co., Ltd. Pharmaceutical composition for treating or preventing inflammatory diseases
US8569375B2 (en) * 2008-08-22 2013-10-29 Reckitt Benckiser Healthcare (Uk) Limited Compositions
CA2739465C (en) 2008-10-03 2017-01-31 Dr. Falk Pharma Gmbh Compositions and methods for the treatment of bowel diseases with granulated mesalamine
EP2340812A1 (en) 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production
RU2463055C2 (ru) * 2011-01-12 2012-10-10 Петр Леонидович Щербаков Способ лечения воспалительных заболеваний кишечника
CN102319218B (zh) * 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
WO2013144176A1 (en) 2012-03-30 2013-10-03 Laboratorios Del Dr. Esteve, S.A. Controlled release formulatin comprising mesalamine
RU2752082C1 (ru) * 2020-09-29 2021-07-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Средство с гранулами, содержащими 5-аминосалициловую кислоту и фолиевую кислоту, с контролируемым высвобождением

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981002671A1 (en) * 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
FR2649611A1 (fr) * 1989-07-13 1991-01-18 Philippe Perovitch Procede de preparation galenique d'une composition therapeutique notamment a base d'aspirine
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon

Also Published As

Publication number Publication date
ATE205704T1 (de) 2001-10-15
SI0871434T2 (sl) 2008-04-30
SI0871434T1 (en) 2002-04-30
PL186790B1 (pl) 2004-02-27
DE871434T1 (de) 2001-04-05
RU2181043C2 (ru) 2002-04-10
NO982904D0 (no) 1998-06-22
CA2240281C (en) 2007-02-27
KR19990076584A (ko) 1999-10-15
IS4772A (is) 1998-06-15
BG63484B1 (bg) 2002-03-29
KR100598714B1 (ko) 2006-07-10
CN1155369C (zh) 2004-06-30
SK83498A3 (en) 1999-01-11
EE9800191A (et) 1998-12-15
TR199801158T2 (xx) 1998-09-21
NO320498B1 (no) 2005-12-12
DE69615400T3 (de) 2008-08-07
DK0871434T4 (da) 2008-04-07
NZ325201A (en) 1998-11-25
IL124858A (en) 2003-03-12
HK1017615A1 (en) 1999-11-26
WO1997023199A1 (en) 1997-07-03
EP0871434B1 (en) 2001-09-19
KR20050087886A (ko) 2005-08-31
IS1834B (is) 2002-11-15
BR9612213A (pt) 1999-12-28
JPH11510191A (ja) 1999-09-07
CA2240281A1 (en) 1997-07-03
ES2149733T5 (es) 2008-05-01
EE03740B1 (et) 2002-06-17
PT871434E (pt) 2002-02-28
CZ289290B6 (cs) 2001-12-12
AU1366197A (en) 1997-07-17
UA67721C2 (en) 2004-07-15
JP4714836B2 (ja) 2011-06-29
SK282669B6 (sk) 2002-11-06
ES2149733T3 (es) 2002-04-01
BG102556A (en) 1999-02-26
HU228856B1 (en) 2013-06-28
EP0871434A1 (en) 1998-10-21
EP0871434B2 (en) 2007-12-12
DE69615400D1 (de) 2001-10-25
DK0871434T3 (da) 2002-01-07
CN1207672A (zh) 1999-02-10
AU702934B2 (en) 1999-03-11
HUP0001084A3 (en) 2000-12-28
DE69615400T2 (de) 2002-05-23
PL327323A1 (en) 1998-12-07
IL124858A0 (en) 1999-01-26
CZ194698A3 (cs) 1998-10-14
HUP0001084A2 (hu) 2000-11-28
KR100542544B1 (ko) 2006-05-10
NO982904L (no) 1998-06-22

Similar Documents

Publication Publication Date Title
ES2149733T3 (es) Composicion farmaceutica oral de liberacion modificada que contiene 5-asa y metodo para el tratamiento de enfermedades intestinales.
ES2084174T3 (es) Productos y procesos para el tratamiento del conducto alimentario.
ES2074698T3 (es) Composicion oral para el tratamiento de enfermedades intestinales inflamatorias.
ES2148365T3 (es) Preparacion farmaceutica controlada para liberar ingrediente activo medicinal en un lugar diana en el tracto intestinal.
ES2157944T3 (es) Nucleos de pastillas de liberacion inmediata de medicamentos insolubles que poseen un recubrimiento de liberacion sostenida.
CO4750822A1 (es) Formulaciones farmaceuticas tada para la administracion en el tracto gastrointestinal y procesos para elaborar las mismas
ES488168A0 (es) Proceso para la preparacion de tabletas farmaceuticas o medicinales de administracion oral, con liberacion retardada delagente activo, en tabletas en las que la cantidad de libera-cion del agente activo es predeterminada.
HUT63564A (en) Medical preparatives, method for producing them and their applications as analgetic and/or febrifuge in human and veterinary medicine
MX9605940A (es) Compuestos bioaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
PT1017404E (pt) Formulacao farmaceutica para o tratamento de doenca inflamatoria do intestino
BR0016469A (pt) Composição para melhorar a resposta proliferativa durante a adaptação do trato gastrointestinal e uso na sìndrome do intestino delgado
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
HRP20070122A2 (en) Medicinal solution for disorder of the alimentary tract
MD1780F1 (en) Method of treatment of patients with hepatic cirrhosis
JPS5219929A (en) Processing unit to select names of diseases
YU66903A (sh) Enterosolventne tablete sa acetilsalicilnom kiselinom
ECSP003646A (es) Metodo para mejorar la piel y el pelaje de mascotas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 871434

Country of ref document: ES